课题基金 / 基金详情

DYSTONIA TREATMENT BY BOTULINUM TOXINS

DYSTONIA TREATMENT BY BOTULINUM TOXINS
肉毒杆菌毒素治疗肌张力障碍
批准号:
3265587
负责人:
ALAN B SCOTT
金额:
$10.99万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-12-01 至 1992-11-30

项目摘要

项目成果

ALAN B SCOTT的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(主要研究人员摘要)A型肉毒杆菌毒素 成为治疗局限性肌张力障碍的有效药物。少校 这种方法的问题是,一些患者会产生抗体 这种药物,几乎所有人都希望在每次服用后都能持续更长时间 注射。在这个项目中,我们将在动物和人类身上进行开发和测试 肉毒杆菌毒素B、D、E、F对眼睑和眼外的影响 肌肉功能,以确定: 1)如果对A型肉毒毒素产生抗药性的患者 其他类型的帮助; 2)如果这些毒素与目前使用的A型毒素有不同的影响 毒素; 3)如果毒素在一起使用时具有协同作用,则具有更大的 与单独使用时相比,有效或持续时间更长; 4)如果组合毒素的抗原性低于单个毒素。
英文摘要
DESCRIPTION: (Principal Investigator's Abstract) Botulinum A toxin has emerged as a useful drug for treatment of focal dystonias. The major problems with this approach are so that some patients develop antibodies to the drug, and almost all would like to see it last longer after each injection. In this project we will develop and test in animals and humans the effect of botulinum toxins B, D, E and F on eyelid and extraocular muscle function, to determine: 1) if patients who have become resistant to type A botulinum toxin can be helped by other types; 2) if these toxins have different effects than the currently used type A toxin; 3) if toxins are synergistic when used together, having either greater effect or greater duration of action than when used singly; 4) if combinations of toxins are less antigenic than individual toxins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Extraocular Muscle (EOM) Responses to Bupivacaine Injection
SELECTIVE REMOVAL OF EXTRAOCULAR MUSCLE
SELECTIVE REMOVAL OF EXTRAOCULAR MUSCLE
SELECTIVE REMOVAL OF EXTRAOCULAR MUSCLE
海外基金